IOBT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

Stats
Today's Volume	78 011.00
Average Volume	137 241
Market Cap	94.87M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.730
ATR14	$0.0120 (0.82%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Zocca Mai-britt	Buy	750 000	Stock Option (Right to Buy)
2024-03-15	Sullivan Amy	Buy	280 000	Stock Option (Right to Buy)
2024-03-15	Smith Devin Whittemore	Buy	185 000	Stock Option (Right to Buy)
2024-03-15	Burkavage Brian	Buy	50 000	Stock Option (Right to Buy)
2024-03-15	Ahmad Qasim Iftikhar	Buy	280 000	Stock Option (Right to Buy)

INSIDER POWER
96.13
Last 87 transactions
Buy: 67 695 200 \| Sell: 7 604 578

Volume Correlation

Long: -0.07 (neutral)

Short: -0.34 (neutral)

Signal:(57.63) Neutral

IO Biotech, Inc. Correlation

10 Most Positive Correlations
PTRA	0.957
FRST	0.952
SGMO	0.951
MOFG	0.95
SMBC	0.944
SPFI	0.943
CBAN	0.942
ABCB	0.941
ALTO	0.941
FMBH	0.94

10 Most Negative Correlations
DRNA	-0.906
SGEN	-0.889
RPHM	-0.884
BLPH	-0.881
TZPS	-0.88
EBACU	-0.88
KBAL	-0.879
ALDX	-0.879
MLAI	-0.879
QADB	-0.876

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

IO Biotech, Inc. Correlation - Currency/Commodity

0.20
( neutral )

0.27
( neutral )

0.00
( neutral )

0.20
( neutral )

-0.23
( neutral )

IO Biotech, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-756 000 (0.00 %)
EPS:	$-1.980

Q4	2023
Revenue:	$1.11M
Gross Profit:	$909 000 (81.89 %)
EPS:	$-0.400

Q3	2023
Revenue:	$0
Gross Profit:	$-194 000 (0.00 %)
EPS:	$-0.430

Q2	2023
Revenue:	$0
Gross Profit:	$-187 000 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.